Last updated on January 2019

A Study to Evaluate the Pharmacokinetics Efficacy and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer


Brief description of study

This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.

Clinical Study Identifier: NCT03493854

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number WO40324 ...

Iem-Fucam
D.f., Mexico
0.26miles

Reference Study ID Number WO40324 ...

Consultorio de Medicina Especializada; Dentro de Condominio San Francisco
Mexico City, Mexico
5.11miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.